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Single-Nucleotide Polymorphisms 
in Inflammatory Bowel Disease
Ewa Dudzińska
Abstract
Inflammatory bowel disease (IBD) mainly includes ulcerative colitis (UC) and 
Crohn’s disease (CD). Both conditions are characterized by chronic inflammation 
of the gastrointestinal tract, with alternating periods of relapse and remission. 
Both forms of IBD involve an uncontrolled inflammatory process in the intestines, 
leading to worsening quality of life and requiring long-term medical and/or surgical 
intervention. Epidemiological and clinical studies suggest that the pathogenesis of 
inflammatory bowel disease is strongly linked to genetic predisposition. CD and UC 
are considered polygenic diseases in which familial clustering is observed in 5–10% 
of patients. Among genetic factors associated with IBD development, it has been 
found that many single nucleotide polymorphisms are associated with susceptibility 
to IBD progression. SNP can affect the production or function of a protein and thus 
affect the development of the disease. However, although the overall role of genes 
involved in the development of IBD is already in most cases known, as of today it is 
unclear how the SNPs in these genes affect cellular function, or how such changed 
cellular functions would contribute to the development of IBD. In the present 
work several selected polymorphisms in genes involved in IBD development are 
discussed.
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1. Introduction
Inflammatory bowel disease (IBD) mainly includes ulcerative colitis (UC) and 
Crohn’s disease (CD). Both conditions are characterized by chronic inflammation 
of the gastrointestinal tract, with alternating periods of relapse and remission. 
Both forms of IBD involve an uncontrolled inflammatory process in the intestines, 
leading to worsening quality of life and requiring long-term medical and/or surgical 
intervention [1].
The pathomechanism of IBD is still not well explain, but evidence suggests 
that it results from perturbation of the homeostasis between the intestinal micro-
biota and the mucosal immune system, with the involvement of both genetic and 
 environmental factors [2].
Ulcerative colitis is a chronic inflammatory disease, which mainly affects the 
large intestine. Typical clinical symptoms of UC are diarrhea, rectal bleeding, and 
abdominal pain. Nonspecific symptoms include fever, appetite loss, and weight 
loss. The disease significantly affects the patient’s quality of life due to its repeated 
remissions and relapses [3].
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UC is characterized by recurring episodes of inflammation limited to the 
mucosal layer of the colon and practically invariably involves the rectum and may 
extend in a proximal and continuous fashion to involve other portions of the colon. 
Endoscopic features of inflammation include loss of vascular markings, granular-
ity and friability of the mucosa, and erosions. In the setting of severe inflamma-
tion is observed deep ulcerations and spontaneous bleeding [4] (Figure 1). CD is 
described by transmural rather than superficial mucosal inflammation and by skip 
lesions rather than continuous disease [5].
In Crohn’s disease, inflammatory changes may occur in all parts of the gas-
trointestinal tract, from the oral cavity to the rectum, but are usually localized 
in the terminal segment of the small intestine, that is, the ileum. Inflammatory 
changes are discontinuous and affect the entire thickness of the intestinal wall. 
The most common symptoms of CD are abdominal pain, fever, weight loss, and 
diarrhea [6].
The commonly used instrument for evaluating the disease severity of CD is 
Crohn’s Disease Activity Indicator (CDAI; remission <150 score, severe disease >450 
score). Whereas the Mayo score (0—normal, 3—severe disease) is used to assess the 
severity of ulcerative colitis [7].
The optimal goal of management in IBD is a durable period of steroid-free 
remission and the induction and subsequent maintenance of mucosal healing [4]. 
Mucosal healing is predominantly defined by endoscopic assessment of intestinal 
inflammation and is referred to as the absence of mucosal ulcerations in CD, while 
in UC, an international consensus defined it as the absence of friability, blood, 
erosions, and ulcers of the gut mucosa. However, these indices allow to determine 
improvements of endoscopic lesions, even when the rather rigid endpoint of 
mucosal healing, and thereby the total disappearance of all mucosal ulcerations is 
not met [8] (Figure 2).
Many genes, which may be linked to IBD, are believed to be associated with 
microbiological defense mechanisms involving the epithelial barrier and innate, 
adaptive immune systems [9].
Figure 1. 
Endoscopic images of ulcerative colitis according to the Mayo score (Grade 3—severe disease). (Source: Own 
study.)
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In the result of large cohort genome-wide association studies (GWAS) of cases 
and controls, over 200 IBD susceptibility loci have now been reported [10].
GWAS research was aimed at searching the SNPs that are over-represented 
in IBD patients when compared with healthy controls. SNPs that occurred more 
frequently in IBD patients are thus called disease-associated variants [11].
Among the genetic factors involved, there are several single-nucleotide poly-
morphisms (SNP) associated with the susceptibility to IBD progression. Many of 
these mutations regulate immune responses with several being enriched in immune 
cells, in particular CD4+ T cells and dendritic cells [12].
2.  Single-nucleotide polymorphisms in innate and adaptive immunity 
genes in IBD
The latest research on genetics and immunology has confirmed that the innate 
immune system is of great importance in inducing intestinal inflammation [13], 
and the publication of Dudzińska et al. [14], “Single nucleotide polymorphisms 
in selected genes in inflammatory bowel disease,” is dedicated to this issue. This 
paper attempts to demonstrate polymorphisms NOD2/CARD15 (nucleotide-binding 
oligomerization domain containing 2/caspase recruitment domain family number 15) 
and the DLG5 gene (discs large homolog 5) in patients with IBD hospitalized at the 
Department of Gastroenterology, Regional Specialist Hospital, SPZOZ im. Stefan 
Cardinal Wyszynski in Lublin.
NOD2/CARD15 is located on chromosome 16q12.1 and was the first disease-
susceptibility gene discovered for CD. NOD2/CARD15 is a pattern-recognition 
receptor that is involved in the homeostasis of intestinal immunity [15].
CARD15/NOD2 plays an important role in immune function. In response to 
bacterial infection, CARD15/NOD2 acts as an intracellular bacterial receptor and 
activates the kappa B nuclear factor (NF-κB), particularly after recognizing the 
bacterial wall component muramyl dipeptide (MDP) [16].
Figure 2. 
Endoscopic assessment of the large intestine was observed by mucosal bridging and pseudopolyps, which 
confirms regeneration of the mucosa in the course of remission of ulcerative colitis. (Source: Own study.)
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NOD2/CARD15 mutations lead to dysregulation of host-microbe interactions, 
contributing to the development of inflammation in the ileum, which is characteris-
tic of CD [17].
Today more than 60 polymorphisms of this gene have been identified; however, 
three common mutations Leu1007fsinsC, Arg702Trp, and Gly908Arg have been 
specifically associated with ileal involvement, stricturing complications, and earlier 
age of onset [18].
While the gene DLG5 encodes scaffold proteins belonging to the MAGUK 
family, which participate in the formation of cellular connections, maintenance 
of cell shape, and intracellular signal transduction [19]. Expression of this gene 
is widely expressed in the tissues of the small and large intestines. DLG5 gene 
polymorphisms have been shown to increase susceptibility to IBD, including 
both CD and UC [20]. DLG5 has been shown to be localized at cell-cell contact 
sites and is involved in maintaining epithelial integrity. Different variants of 
DLG5 may contribute to the loss of cell polarization complexes and adhesion 
complexes, so that epithelial cell polarity is not maintained, and epithelial-
mesenchymal transition (EMT) is induced [20]. EMT is a process involving the 
transformation of immobile, polarized cells with an epithelial phenotype into 
cells with a mesenchymal phenotype. The characteristic features of EMT include 
lack of polarity and cell adhesion, reduced expression of E-cadherin, and 
increased mobility and invasion capacity [21].
Thus, it can be assumed that DLG5 polymorphisms may impair the epithelial 
barrier in the gastrointestinal tract and lead to abnormal epithelial structure, 
making it more susceptible to IBD (CD and UC). Furthermore, the DLG5 scaffold 
protein also belongs to the CARD family of proteins (like CARD15/NOD2). Thus, 
DLG5 is probably involved in the regulation of NF-κB activation or caspase activa-
tion within the host defense mechanisms [22]. Therefore, both the NOD2 and DLG5 
genes may interact functionally to contribute to the risk of developing CD.
Our research in the group of patients diagnosed with CD and UC is related to the 
occurrence of polymorphisms in the NOD2 and DLG5 genes.
The test material was blood collected from patients on an empty stomach after 
12 hours of rest. In addition, medical history was taken with regard to the occur-
rence of extraintestinal symptoms and autoimmune diseases in the family. The 
family history of all subjects was negative. DNA was isolated using a QIAamp DNA 
Blood Mini Kit (QIAgen), followed by quantitative and qualitative evaluation of the 
isolated DNA samples.
The following primers were used for PCR: (F) 
GACTCTTTTGGCCTTTTCAGATT and (R) CCAATGGTCTTTTTTCCTTACTCC 
for CARD15/NOD2 and (F) TTATTCCCCTTCCACAGGCACTAC and (R) 
GCCGCAGCTGAATGGAGA for DLG5.
The PCR product was sequenced, and the sequences obtained were recorded in 
FASTA format. The nucleotide sequences of the CARD15/NOD2 and DLG5 gene 
fragments were compared using DNA Baser software.
The size of the analyzed CARD15/NOD2 gene fragment was 243 bp. No SNPs 
were observed in this fragment in patients with CD or UC.
Although numerous reports confirm that CARD15/NOD2 gene polymor-
phisms are associated with a predisposition to IBD [23], our research did not 
show this relationship. This may be linked to the absence of parenteral symptoms 
in the subjects.
One of the most common single-nucleotide polymorphisms of the CARD15/
NOD2 gene is P268S (SNP5), where the cytosine residue at position 802 is replaced 
by thymine. In the Polish population, P268S polymorphism has been found in 
49.5% of patients with CD, and its presence in both alleles is associated with earlier 
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onset of disease symptoms and increased risk of parenteral symptoms such as joint 
abnormalities, iritis, and erythema nodosum [24].
The size of the DLG5 gene fragment was 107 bp. One SNP at position 1,248,696 
was found in the gene fragment. A T > C substitution occurred in one sample 
(Patient 3) from the group of patients with Crohn’s disease (Figure 3). Other 
authors note that the R30Q (Rs1248696) variant of DLG5, where amino acid 30 in 
exon 3 changes from arginine to glutamine, is associated with the development of 
IBD [25].
Despite numerous reports indicating the presence of polymorphisms of the 
NOD2/CARD15 gene, our studies did not show the position of SNP in patients with 
IBD from the Lublin region. The study suggests that SNPs (T > C substitution) 
affect the function of the DLG5 protein and thus play a role in the development of 
IBD, in particular Crohn’s disease.
3. The role of autophagy genes in the pathogenesis of IBD
Autophagy is a conserved lysosome-dependent catabolic process, degrading 
and recycling protein aggregates or damaged organelle. Autophagy affects the 
pathogenesis of IBD in multiple ways, including secretion of antimicrobial materi-
als from Paneth cells, clearance of invading pathogens, presentation of antigen, or 
proinflammatory cytokine production by macrophages [26].
SNPs of autophagy genes such as autophagy-related gene 16 like 1 (ATG16L1) 
and immunity-related GTPase family M (IRGM) have been identified to be associ-
ated with CD. ATG16L1 and IRGM genes affect cellular autophagy processes and 
bacterial clearance in immune cells and may affect bacterial composition of the gut 
in patients with IBD [27].
There is some overlap in these autophagy-related genetic variants in both CD 
and UC, but majority of the identified variants are more associated with ileal 
CD. Despite this association, the positive predictive value for disease development 
in individuals carrying autophagy variants is low because the ATG16L1 T300A 
polymorphism is linked with CD susceptibility, which is also present in a large 
proportion of healthy individuals who do not develop IBD [28].
Figure 3. 
SNP at position rs1248696, T > C substitution in a patient with Crohn’s disease (source: Dudzińska et al. 2018).
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However, some of the studies show that a knock-in mouse model expressing 
ATG16L1 T300A does not develop spontaneous inflammation, but it exhibits mor-
phological defects in both Paneth cells and goblet cells, and the presence of the T300A 
mutation in ATG16L1 leads to aberrant functionality of Paneth cells. These findings 
indicate a close relationship between ATG16L1 variants and Paneth cells [15].
Recent data GWAS identified the single-nucleotide polymorphism (SNP) 
rs13361189—a SNP lying immediately upstream of the autophagy gene IRGM, and 
many studies have investigated IRGM gene variants both in adult and pediatric and in 
UC, confirming its role in the IBD pathogenesis. It was shown that SNP rs13361189, 
the deletion allele, modulated the expression of IRGM in transformed cells [29].
Other study demonstrated functional effects of the synonymous SNP 
rs10065172 (c.313C > T). This synonymous variant rs10065172 in IRGM alters a 
binding site for certain microRNAs, miR-196, and causes deregulation of IRGM-
dependent xenophagy of bacteria in patients with CD [29].
4. AHR and its role in regulating intestinal inflammation
Tryptophan metabolism plays important roles in the pathogenesis and therapeu-
tics of IBD [30]. Recent study investigates the interaction between Card9 and the gut 
microbiota in the generation of the microbiota-derived tryptophan metabolite [2].
Tryptophan can be metabolized either by the gut bacteria into indole deriva-
tives, such as indole-3-acetic acid (IAA), or by host cells into kynurenine (Kyn) via 
indoleamine 2,3-dioxygenase 1 (IDO1) [31].
Kyn derived from host metabolism, and indole-derived tryptophan metabolites 
produced by gut microbiota are endogenous ligands of aryl hydrocarbon receptor 
(AHR), an important regulator of immune response. AHR disturbance results in 
disordered immune responses, including decreased Treg cell levels and increased 
TNF-α levels, and a modified timeframe of IL-10 and IL-12 secretion. Elevated the 
serum levels of tryptophan metabolites including kynurenic acid (KA) is potential 
aryl hydrocarbon receptor (AHR) ligands to impact colitis. Several findings suggest 
that KA and other tryptophan metabolites inhibit the colonic inflammation [30].
Although polymorphisms in AHR have not yet been associated with IBD, AHR 
is known to play a central role in the regulation of intestinal inflammation and is 
upregulated in the inflamed gut [12].
SNPs are common, single-nucleotide genetic variants that can influence protein 
function, protein stability, or gene expression. Genome-wide association studies and 
candidate gene studies have identified SNPs near AHR target genes that are significantly 
associated with AHR-regulated phenotypes, such as psoriasis (CYP1A1) and systemic 
lupus erythematous (CYP1A1). These findings suggest that SNPs near AHR-binding 
sites might impact AHR target gene expression and contribute to individual variation in 
disease risk and pharmacotherapy phenotypes. Of interest, that SNP is distant from an 
AHR response element (AHRE) but still influences AHR binding and CYP1A1 expres-
sion after AHR agonist treatment, which suggests that it may influence the stability of 
the AHR complex and its ability to regulate CYP1A1 gene expression [32].
It is also important that over the last years, some functions of noncoding DNA 
have been discovered, and the role of regulatory sequences in transcriptional 
regulation, development of the disease process, and determination of cell type 
specificity is nowadays widely appreciated [11].
In the latest research, Boyd et al. [33] presented Cap Analysis of Gene 
Expression (CAGE) analysis on biopsies from the descending colon from 94 IBD 
patients and controls. These data enabled annotation of IBD-regulated enhanc-
ers and transcription start sites (TSSs) and characterization of IBD-associated 
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SNPs in such regions. Researchers have shown that clear overrepresentation of 
IBD-associated SNPs in both IBD upregulated enhancer and promoter regions also 
presented regions that had the largest IBD heritability enrichment compared to 
other genomic regions. The results of these studies carried out many resources for 
interpretation of the functional impact of noncoding genetic variants [33].
5. SNPs in the multi-drug resistance 1 gene
Another of the genes whose mutations may play a role in the pathogenesis of IBD 
is multi-drug resistance 1 (MDR1) gene. MDR1 encodes P-glycoprotein 170 (P-gp), 
an ATP-dependent drug transport efflux pump, which highly expressed in many 
cells and epithelial surfaces, including the epithelium of GI tract [34].
In the gut, P-gp is expressed on the apical surfaces of the superficial columnar 
epithelial cells in the intestine with the levels of expression gradually rising from the 
duodenum to the distal parts of the intestine with the highest levels of expression in 
the distal small bowel and colon [35].
It is now known that substrates for the P-gp pump include a variety of structur-
ally and pharmacologically distinct hydrophobic compounds, such as drugs and 
toxins, and P-gp might also play a critical role in host bacterial interactions in the 
gastrointestinal tract and maintenance of intestinal homeostasis [34].
SNPs of MDR1 can occur naturally in humans, but some of them were related 
to altered P-gp expression and function. Three most common SNPs that have been 
repeatedly shown to predict changes in the function of P-gp are synonymous SNPs 
C1236T (rs1128503) in exon 12 and C3435T (rs1045642) in exon 26 and nonsynony-
mous, triallelic SNP G2677T/A (Ala893Ser/Thr or rs2032582) located in exon 21. 
In German, studies have been shown that both T allele and TT genotype of C3435T 
polymorphism were more frequently present among UC subjects, and the associa-
tion of G allele of 2677 and IBD was also shown in North American study. However, 
further research that analyzed different allele combinations of those SNPs in IBD 
patients gave conflicting results [34].
6. SNPs in the neutrophil cytosolic factor 4 gene
More recently, GWAS has identified a number of new genetic susceptibility 
factors for IBD. Of these, new candidates have confirmed the association of the 
proinflammatory cytokine interleukin-23 receptor subunit (IL-23R) with CD and 
UC and a second gene, neutrophil cytosolic factor 4 (NCF4) with CD [36].
Researchers, Nuij et al. [27], have demonstrated that an IBD-associated SNP in 
the neutrophil cytosolic factor 4 (NCF4) gene results in a decreased antimicrobial 
function of granulocytes, as demonstrated by a reduced production of reactive 
oxygen species by these cells [27]. Moreover, as recently shown, SNPs in the inter-
leukin 23 receptor gene (IL23R) have affected to express the anti-microbial peptide 
DMBT1 in intestinal epithelial cells in IBD [27].
7. Conclusion
Chronic inflammatory bowel disease is a subject of great interest among 
researchers because the pathomechanism of these conditions is difficult to explain, 
and thus far there is no optimal therapeutic process completely eliminating the 
symptoms and effects of the disease [37, 38].
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Epidemiological and clinical studies suggest that the pathogenesis of inflamma-
tory bowel disease is strongly linked to genetic predisposition [39, 40].
CD and UC are considered polygenic diseases in which familial clustering is 
observed in 5–10% of patients [41].
Among genetic factors associated with IBD development, it has been found that 
many single-nucleotide polymorphisms are associated with susceptibility to IBD 
progression. SNP can affect the production or function of a protein and thus affect 
the development of the disease [14].
However, although the overall role of genes involved in the development of IBD 
is already in most cases known, as of today it is unclear how the SNPs in these genes 
affect cellular function, or how such changed cellular functions would contribute to 
the development of IBD [27]. Therefore, further research is needed to demonstrate 
how gene polymorphism leads to the development of IBD.
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